Valeo Pharma (TSX:VPH) Retained Earnings : C$-105.14 Mil (As of Jul. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Valeo Pharma Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Valeo Pharma's retained earnings for the quarter that ended in Jul. 2024 was C$-105.14 Mil.

Valeo Pharma's quarterly retained earnings declined from Jan. 2024 (C$-89.14 Mil) to Apr. 2024 (C$-96.95 Mil) and declined from Apr. 2024 (C$-96.95 Mil) to Jul. 2024 (C$-105.14 Mil).

Valeo Pharma's annual retained earnings declined from Oct. 2021 (C$-28.71 Mil) to Oct. 2022 (C$-54.46 Mil) and declined from Oct. 2022 (C$-54.46 Mil) to Oct. 2023 (C$-82.26 Mil).

Valeo Pharma Retained Earnings Historical Data

The historical data trend for Valeo Pharma's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Valeo Pharma Retained Earnings Chart

Valeo Pharma Annual Data

Trend

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Retained Earnings

Get a 7-Day Free Trial

-9.72

-14.48

-28.71

-54.46

-82.26

Valeo Pharma Quarterly Data
	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24
Retained Earnings	Get a 7-Day Free Trial															-73.02	-82.26	-89.14	-96.95	-105.14

Valeo Pharma Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Valeo Pharma (TSX:VPH) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Valeo Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Valeo Pharma Inc (TSX:VPH) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

N/A

Address

16667, Hymus Boulevard, Kirkland, QC, CAN, H9H 4R9

Website

https://www.valeopharma.com

Valeo Pharma Inc is a Canadian specialty pharmaceutical company focused on acquiring either through acquisitions, in-licensing, or similar arrangements. The company operates in two divisions: Branded prescription products and hospital specialty products. Its product portfolio includes medicines for Respiratory/Allergy, Ophthalmology, Neurology, and Oncology.

Executives

Luc Mainville	Senior Officer
100079 Canada Inc.	10% Security Holder
Richard J. Mackay	Director, Director or Senior Officer of 10% Security Holder
Steve Saviuk	Director, Director or Senior Officer of 10% Security Holder, Senior Officer
Jeffrey Michael Skinner	Senior Officer
Frederic Fasano	Director
Guy Paul Allard	Director or Senior Officer of 10% Security Holder, Senior Officer
Marc François Léger	Senior Officer

Valeo Pharma Headlines

No Headlines